Neuroendocrine Neoplasia

This reference work  provides comprehensive data about neuroendocrine neoplasms. 
Written by some of the most noted experts across 5 continents, this book provides innovative classification and all the recent advances in tumor biology and molecular characterization, as well as in diagnosis, definition of prognosis and treatment of neuroendocrine neoplasia. 
This book is a reference tool for practitioners involved in the management of patients, namely oncologists, endocrinologists, gastroenterologists, radiologists, surgeons, pathologists, biologists, as well as other specialists facing patients with neuroendocrine neoplasia because of peculiar aspects (cardiologists, pneumologists, nutritionists, psychologists).  It is published as part of the SpringerReference program, which offers access to "living" editions constantly updated through a dynamic peer-review publishing process.

List of contents

Epidemiology of NENs (incidence, prevalence, survival, environmental risk factors).- Pathological classification (GEP, TNET and rare forms).- Tumor staging (TNM).- Genetic drivers of NENs.- Clinical and molecular prognostic factors in NENs.- Clinical presentation of functioning and nonfunctioning NEN.- Work up of newly diagnosed NENs.- Role of functional imaging in NENs.- Role of circulating neuroendocrine markers.- Management of functioning syndrome.- Role of surgery: curative intent.- Role of surgery: metastatic disease.- Role of liver directed therapy in NENs.-  Systemic therapy for metastatic disease: GEP NENs.- Systemic therapy for metastatic disease: lung NEN.- Role of therapeutic PRRT in NENs.- Management of unknown primary metastatic NEN.- Future trends in NEN care: QoL and multi-disciplinary care.

About the author

Antongiulio Faggiano
is Full Professor of Endocrinology at the Department of Clinical and Molecular Medicine, Sapienza University, Sant’Andrea University Hospital of Rome. He is a key opinion leader in the field of neuroendocrine neoplasms such as NET and medullary thyroid cancer. He is nationally and internationally recognized as expert in the field of neuroendocrine neoplasms and endocrine tumours, with special interest in the field of therapy with somatostatin analogues and dopamine agonists, targeted therapies, biomarkers for diagnosis, prognosis and response to therapy. He has been a member of the Advisory Board of the European Neuroendocrine Tumor Society, the main international Society of neuroendocrine neoplasms. He has been involved as participating centre or PI in several phase 2-3 trials for neuroendocrine and thyroid cancer. He is author of more than 300 full papers in international peer reviewed journals, the most part on neuroendocrine tumors and genetic endocrine syndrome.

Diego Ferone
is Full Professor of Endocrinology at the Department of Internal Medicine and Medical Specialties, Director of the Postgraduate School of Endocrinology and Metabolism, and Chief of the Endocrine Unit at the University of Genova, as well as Director of the Department of Internal Medicina at the San Martino University Hospital in Genova. Currently he is a President of the Italian Endocrine Society where he also served as Treasurer and General Secretary, Past Secretary of the Italian Society of Andrology and Sexual Medicine, a member of the Advisory Board of the European Neuroendocrine Tumor Society, a past member of the Executive Committee of the European Neuroendocrine Association, and a member of several journal Editorial Boards. After obtaining his degree in Medicine and postgraduate degree in Endocrinology and Metabolic Diseases at the Federico II University of Naples, Dr Ferone received his PhD in Neuroendocrinology at Erasmus University in Rotterdam supervised by prof. Steven Lamberts and Leo Hofland. He was awarded Best Young Investigator in 1999 and received the Career Award in 2011 by the Italian Endocrine Society, and the award of Best Italian Researcher in 2010 in the field of neuroendocrine tumours and multiple endocrine neoplasia. Dr Ferone has been constantly involved in studies on the physiopathology and treatment of pituitary and neuroendocrine tumours, physiopathology of somatostatin and dopamine receptors in the immune and neuroendocrine systems, and medical therapy of acromegaly, Cushing’s disease, neuroendocrine tumours, and hypopituitarism; he has authored more than 350 peer-reviewed articles.

Simron Singh
is a Professor of Medicine at the University of Toronto and a medical oncologist at Odette Cancer Center, Sunnybrook Health Sciences Center in Toronto, Canada. He is the co-founder of He completed his BSc as well as MD at University of Alberta in Edmonton, Alberta. He completed postgraduate training in Internal Medicine at Queens University in Kingston, Ontario, Canada and Medical Oncology at the University of Toronto. After completing his clinical training, Dr Singh completed his Master's degree in Public Health from Harvard University in USA. Dr Singh is a global leader in the field of Neuroendocrine cancers. He has led major practice changing global clinical trials as well as guidelines. Besides being an international sought after speaker he has published in numerous high impact journals in this area including Lancet, Journal of Clinical Oncology and JAMA. He co-established the Susan Leslie clinic for neuroendocrine cancers – the first of its kind in the region.

Product details

• Assisted by: Antongiulio Faggiano (Editor), Diego Ferone (Editor), Simron Singh (Editor)
• Publisher: Springer, Berlin
• Languages: English
• Product format: Hardback
• Release: 09.01.2026
• EAN: 9783031832802
• ISBN: 978-3-0-3183280-2
• No. of pages: 413
• Illustrations: XIX, 413 p. 24 illus., 4 illus. in color.
• Series: Endocrinology
• Subjects: Natural sciences, medicine, IT, technology > Medicine > Clinical medicine; Management, Onkologie, Imaging, Therapy, Endocrinology, Oncology, neuroendocrine tumors, prognostic factors, Neuroendocrine cancers